Best Life Sciences Companies in District of Columbia, United States
The 56 best Life Sciences companies in District of Columbia, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Cartesian Therapeutics.
Our analysis of 164 Life Sciences companies
$34.7b in tracked funding; 83% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Life Sciences companies in District of Columbia
| # | Company | Disclosed funding | Last round | Employees | Founded | Founder | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | Cartesian Therapeutics Pioneering mRNA cell therapies for autoimmune diseases, expanding treatment possibilities 48Funding top 24%Moat top 37%Fin. health top 42%Growth top 44% All 8 signals ▾Fundingtop 24% Moattop 37% Fin. healthtop 42% Growthtop 44% Markettop 49% Newsbottom 38% Globalbottom 32% Techbottom 26% Funding: Raised $133M across 2 rounds · 2 rounds over 2 yrs (1.0/yr) Moat: Top 15% by revenue among 13 tracked Immunotherapy companies · Editorial + unicorn rating 2/10 rank vs industry peers · Fliar Intelligence Index 48/100 | $133M | 13 mo ago | 26 | 2016 | — | — | 1 partnership |
| 2 | Prestwick Pharmaceuticals Researching neurodegenerative disorders, diagnostics, and providing related research products and services | $112M | 226 mo ago | 29 | 2002 | — | — | — |
| 3 | Otolith Labs Provider of a wearable platform for treating vertigo and motion sickness | $34M | 23 mo ago | 16 | 2015 | Samuel Owen Founder & CEO | — | — |
| 4 | Vanda Pharmaceuticals Developer of pharmaceutical products for treating CNS disorders | $34M | 246 mo ago | 203 | 2003 | Mihael Polymeropoulos CEO & President | 1,026 patents Pharmaceutical formulations and methods for CNS, sleep, oncology, and ophthalmic drugs | — |
| 5 | Chase Therapeutics Developer of drugs for neurodegenerative disorders | $31M | 56 mo ago | 1 | 2008 | Kathleen Clarence-Smith Co Founder and Board Chair | 190 patents Patents concentrated in health & consumer products | — |
| 6 | Sorcero Cloud-based workflow automation solution for life sciences and insurance industries | $16M | 9 mo ago | 15 | 2017 | Richard Graves Co-Founder & CCO | 38 patents AI-powered text summarization and ontology-driven language model enhancement | 1 launch |
| 7 | Hamilton Pharma US-based specialty pharma company developing neurodegenerative disease therapeutics | $11M | 254 mo ago | — | 2004 | Thomas Chase CEO & MD | — | — |
| 8 | Amelia Technologies Provider of molecular diagnostics platforms DNA damage repair | $8M | 12 mo ago | 5 | 2018 | Jack Chrikjian Founder | — | — |
| 9 | NeuroSync Provider of AI-based platform to assess brain health, deliver therapy, and optimize performance | $7M | 102 mo ago | 4 | — | Gary Gregory Chairman & CEO | 2 patents Vision-based cognitive training systems with binocular coordination and timing feedback | — |
| 10 | Remedy Plan Developing first-in-class NAMPT inhibitors for oncology, autoimmune, and metabolic diseases | $7M | 14 mo ago | 10 | 2011 | — | 24 patents Small‑molecule oncology drugs targeting cancer stem cells and NAMPT enzymes | — |
| 11 | Applikate Technologies Provider of automated histology platform for digital imaging | $6M | 30 mo ago | 1 | 2013 | Rick Torres Co-Founder & Co-CEO | — | — |
| 12 | Current Surgical Developer of micro-invasive therapies for the treatment of solid tumors | $4M | 39 mo ago | 4 | 2019 | Christopher Wagner Co-Founder | — | — |
| 13 | Indygeneus Developer of drugs and clinical disease management solutions by using clinical and multi-omics data | $4M | 42 mo ago | 10 | 2020 | Yusuf Henriques Co-Founder & CEO | — | — |
| 14 | Root Sciences Provider of extraction & distillation equipment consulting, installation, setup, and training services for… | $4M | 83 mo ago | — | 2016 | Nenad Yashruti Co-Founder | — | — |
| 15 | Oncovir Biotechnology company developing Hiltonol® immunotherapy for cancer and infectious diseases | $2M | 118 mo ago | 5 | 2004 | Andres M Chairman & CEO | 22 patents Patents concentrated in chemistry & materials | — |
| 16 | 60 Degrees Pharmaceuticals Provider of therapeutics for the treatment and prevention of tropical infectious diseases | $2M | 37 mo ago | 3 | 2010 | Geoffrey Dow Founder & CEO | — | 1 launch |
| 17 | StimuSIL Developer of a therapeutic medical device for dermatology and aesthetics | $2M | 18 mo ago | 7 | 2019 | Pablo Villalba Co-Founder | 7 patents Wearable dermal phototherapy devices delivering therapeutic light to skin. | — |
| 18 | SISCAPA Assay Technologies Immuno-MS assays for protein drugs, targets, and biomarker measurement | $2M | 14 mo ago | 11 | 2011 | — | 27 patents High‑sensitivity single‑molecule peptide sequencing for targeted proteomics assays. | — |
| 19 | SafeGuard Surgical Developer of surgical instruments | $2M | 9 mo ago | — | 2019 | Jill Kelley Co-Founder SafeGuard Surgical™️ | — | — |
| 20 | Rakta Therapeutics Anti-parasitic drugs that specifically target the parasite's variation of HRG1 and HRG3 transporters | $1M | 121 mo ago | — | 2011 | Iqbal Hamza Founder | — | — |
| 21 | Weinberg Medical Physics Medical device incubator developing novel medical devices, interventional technologies, and therapies | $1M | 113 mo ago | 6 | 2006 | Irving Weinberg President & CEO | — | — |
| 22 | Modus Precision activity monitoring solutions for clinical trials, research, and patient care | $465K | 130 mo ago | 7 | 2014 | Jay Althoff CEO | — | — |
| 23 | KRa Drinks Organic energy and sports drinks brand | $425K | 123 mo ago | — | 2015 | Annie Hesser Co-Founder & CMO | — | — |
| 24 | Diagnostic Ansers Cannabis strain reviews, information, and resources for informed decisions | $305K | 121 mo ago | 3 | 2012 | Sean Virgile Co-Founder | — | — |
| 25 | Altrix Medical Innovating medical technologies for disease prevention and treatment with a smartAED | $225K | 89 mo ago | 3 | 2013 | Dan Fleck Co-Founder & CTO | — | — |
Top 12 Life Sciences companies in District of Columbia
#1
Public · Washington, DC, District of Columbia · founded 2016 · 26 employees$133Mraised▾
Pioneering mRNA cell therapies for autoimmune diseases, expanding treatment possibilities. This clinical-stage company is dedicated to revolutionizing the treatment of autoimmune disorders through its innovative mRNA cell therapy platform. With a focus on immunology, the company leverages its proprietary platform and manufacturing capabilities to develop novel therapies. Their approach aims to bring advanced treatments to patients, placing them at the center of innovation. Committed to expanding the reach of cell therapy, they are developing a pipeline of treatments for autoimmune diseases, striving to improve patient outcomes and quality of life. The company's work has potential social impact by addressing unmet needs in autoimmune disease treatment.
- May 2025Grant (prize money)$3M
- Jul 2024Post IPO$130M
#2
Series B · Washington, DC, District of Columbia · founded 2017 · 15 employees$15.7Mraised▾
Cloud-based workflow automation solution for life sciences and insurance industries. It offers an enterprise NLP suite that allows life sciences & insurance industries to handle complex information, policies, rules, and regulations and automates the building of smart knowledge bases and workflows.
- Sep 2025Series B$42.5M
- Sep 2021Series A$10M
- Jun 2020Series A$3.5M
- May 2019Seed$1.7M
#3
Funding Raised · Washington, DC, District of Columbia · founded 2018 · 5 employees$7.7Mraised▾
Amelia Technologies is a provider molecular diagnostics platform DNA damage measurement and repair. The company offers services for carcinogenesis, aging-associated diseases, genome editing protocols and diagnostics platforms. The platform is used to measure a range of endpoints associated with DNA damage and repair.
- Jun 2025Grant (prize money)$274.5K
- Apr 2024Grant (prize money)$274.5K
- Sep 2022Grant (prize money)$1.7M
- Feb 2021Grant (prize money)$1.9M
#4
Series B · Washington, DC, District of Columbia · founded 2011 · 10 employees$6.7Mraised▾
Developing first-in-class NAMPT inhibitors for oncology, autoimmune, and metabolic diseases. This biotech company is pioneering a new approach to targeting NAMPT, a core regulator of human biology, to treat diseases. Their proprietary drug screening platform has led to novel drug chemistry and an unprecedented mechanism of action, avoiding the toxic effects of previous NAMPT-targeting drugs. They are focused on discovering and optimizing new drugs that target core vulnerabilities in cancer cells, autoimmune disorders, and metabolic diseases. The company's science pipeline includes programs in oncology, autoimmune diseases, and obesity. They aim to develop therapeutics that effectively block cancer recurrence and metastasis, as well as treat other diseases linked to NAMPT dysregulation.
- May 2025Series B$18M
- Dec 2019Series A$5.2M
- Nov 2018Series A$1.5M
#5
Series A · Washington, DC, District of Columbia · founded 2015 · 16 employees$33.8Mraised▾
Provider of a wearable platform for treating vertigo and motion sickness. The platform is meant for travelers and virtual reality users. The company leverages its proprietary technology for addressing the problem of the vestibular system and eye control balance which causes vertigo and motion sickness. Their non-invasive technology uses a patent-pending transducer which sends consistent and noninformative stimuli to the vestibular system to mitigate the sensation of vertigo and motion-related nausea.
- Jul 2024Series A$4.9M
- Sep 2022Series A$24.8M
- Jun 2021Seed$3.3M
- Oct 2018Seed$750K
#6
Funding Raised · Washington, DC, District of Columbia · founded 2019$1.5Mraised▾
Developer of surgical instruments. The products developed are patented LeakGuard prosthesis is a biodegradable intraluminal stent when placed with intestinal anastomosis to prevent postoperative leaks. The patented SaferStapler is used for circular end-to-end stapling during colorectal and gastric bypass surgery to prevent leaks.
- Sep 2025Grant (prize money)$406.5K
- Feb 2024Conventional Debt$1.1M
#7
Seed · Washington, DC, District of Columbia · founded 2011 · 11 employees$1.6Mraised▾
Immuno-MS assays for protein drugs, targets, and biomarker measurement. The company specializes in developing and performing definitive immunoaffinity-MS assays, offering unprecedented precision, sensitivity, and specificity in protein measurement. Their technology solves challenging protein measurement problems encountered in drug development, clinical trials, and diagnostics, overcoming limitations of conventional immunoassays. They provide custom assay development, automated workflows, and multiplex panels for clinically-established protein targets and biomarkers. Services include peptide selection, immuno-affinity reagent development, assay optimization, and implementation across various matrices. They enable accurate measurement of therapeutic drugs, drug targets, and biomarkers, supporting critical decisions in drug discovery, preclinical studies, clinical trials, and companion diagnostics. Their platform facilitates longitudinal studies using dried blood spots, integrating mobile health components for comprehensive data analysis. The company enhances clinical test quality while reducing costs, driving advancements in proteomics and personalized medicine.
- Apr 2025Seed$2M
- Apr 2014Seed$1M
- Aug 2012Seed$562K
#8
Series A · Washington, DC, District of Columbia · founded 2019 · 7 employees$1.7Mraised▾
Developer of a therapeutic medical device for dermatology and aesthetics. It offers a subdermal photobiomodulation-based device for androgenetic alopecia that delivers stimulation subdermally and stimulates the skin’s biological pathways.
- Dec 2024Series A$600K
- Apr 2024Series A$1.1M
- Aug 2022Seed$569.7K
#9
Funding Raised · Washington, DC, District of Columbia · founded 2013 · 1 employees$5.7Mraised▾
Provider of automated histology platform for digital imaging. The platform automates the pathology workflow, cuts processing time, lowers labor and materials costs, improves image quality, and reduces the risk of misdiagnosis.
- Jan 2024Grant (prize money)$4.1M
- Sep 2019Grant (prize money)$956.3K
- Feb 2019Grant (prize money)$224.7K
- Aug 2015Grant (prize money)$216.6K
#10
Acquired · Washington, DC, District of Columbia · founded 2002 · 29 employees$112Mraised▾
Researching neurodegenerative disorders, diagnostics, and providing related research products and services. The company focuses on advancing research in areas like Huntington's disease and developing diagnostic tools, such as cholera detection methods. It offers a wide array of products and services to support biological research, including antibodies, assay kits, cells, DNA/RNA related products, enzymes, proteins, and various reagents. These offerings cater to researchers in fields like neurodegeneration, Covid-19, and other viral infections. The company supports scientific advancement by providing essential tools and resources for understanding and combating complex diseases. It also supports research into potential therapeutic targets and drug repurposing.
- Aug 2007Series C$20M
- Aug 2007Convertible Debt$59.4K
- Aug 2006Series C$31.8M
- Dec 2004Series B$37M
#11
Series B · Washington, DC, District of Columbia · founded 2008 · 1 employees$30.9Mraised▾
Developer of drugs for neurodegenerative disorders. The lead compound of the company, CTC-501 is for major depressive disorder and CTC-413 for the symptomatic, neuroprotective treatment of Parkinson’s disease and related disorders.
- Oct 2021Series B$20M
- Nov 2017Series A$1.3M
- Feb 2016Series A$3.5M
- May 2014Series A$6.1M
#12
Seed · Washington, DC, District of Columbia · founded 2019 · 4 employees$4Mraised▾
Developer of micro-invasive therapies for the treatment of solid tumors
- Apr 2023Grant (prize money)$400K
- Feb 2023Seed$3.2M
- May 2021Grant (prize money)$256K
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Biotechnology is moving in the United States
A read on the academic research around Biotechnology — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 6,260 United States-affiliated papers.
- Harvard University209
- Cornell University177
- University of Tennessee at Chattanooga140
- Howard Hughes Medical Institute126
- Johns Hopkins University121
- Gene33→164
- Transcription (linguistics)11→79
- Antibody11→62
- Genome6→56
- Mutation7→56
- Gene8→110
- Cell culture3→62
- Gene expression3→62
- Fermentation2→54
- Downregulation and upregulation1→50
- Agriculture19→58
- Antibiotic resistance15→45
- Public health4→31
- Gene6→30
- Production (economics)5→29
Where biotechnology is researched across United States
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Who's filing biotechnology patents in the United States
United States biotechnology patent filing is accelerating — 457,918 filings from 8,000 assignees (2016–2025), led by Genentech, UNIV California, Regeneron Pharma; annual filings 36884→44446.
- Genentech18103
- UNIV California17969
- Regeneron Pharma16083
- Amgen10510
- Monsanto Technology9754
- UNIV Pennsylvania8526
- Harvard College7463
- UNIV Texas7382
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.